55% of pathologist and oncologist survey respondents globally are facing stress and burnout due to increasing complexity and high workloads More than a third highlight burdens they face are detrimental to patient care, and 77% agree...

Owkin’s MSIntuit® CRC v2*, a next-generation AI diagnostic aimed at transforming the detection and treatment of colorectal cancer, will be integrated into Proscia’s Concentriq® software platform, making it available as part of...

Utilizing Owkin’s expansive data network and cutting-edge AI, this solution optimizes pre-screening for gBRCA mutations in breast cancer directly from digitized H&E pathology slides The solution aims to improve gBRCA...

Owkin selects Amazon Web Services (AWS) as its primary cloud provider to develop generative AI applications and accelerate drug discovery and development The company will leverage AWS’s scalable storage options, enhanced data security...

Owkin to collaborate with MSD to develop and commercialize AI-powered digital pathology Microsatellite Instability High (MSI-H) diagnostics for four types of cancer. The aim is to pre-screen patients for the MSI-H biomarker, which is found...

Article in Nature Communications demonstrates that with 96% sensitivity, AI diagnostic MSIntuit™ CRC can  rule  out  almost  half  of  the  MSS population of colorectal cancer patients unlikely to respond to checkpoint...